HIV Commercial Insight: The Battle for the $9.3 Billion Market Share is Getting Fiercer

DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/b776d8/commercial_insight) has announced the addition of the "Commercial Insight: HIV - The Battle for Market Share is Getting Fiercer" report to their offering.

“Commercial Insight: HIV - The Battle for Market Share is Getting Fiercer”

In 2007, HIV drugs achieved sales of $9.3 billion in the 7MM, growing faster than the overall market at a CAGR of 11.3% from 2004-2007. Due to patent expirations, Datamonitor expects the markets growth to slow down somewhat, reaching total sales of $15.1 billion in 2017. Among the ROW, the Canadian HIV market in 2007 was worth $272 million, achieving a CAGR of 24% from 2004-2007.

Scope

- In-depth analysis of the current HIV market across the US, EU, Japan and a ROW snapshot

- Thorough assessment of underlying commercial and clinical factors shaping the antiretroviral market

- Detailed sales forecasts for the major antiretroviral classes, molecules and brands in each of the seven major markets

- Case study analysis of the Canadian market including an in-depth assessment of the healthcare system and potential opportunities and threats

Highlights of this title

Gilead is now the market leader in HIV with a portfolio of just four marketed products. Datamonitor expects JnJ/Tibotec and Merck to be the fastest growing companies over the next 10 years. While Tibotec only entered the field with the launch of its first product in 2006, Merck & Co.s first-in-class Isentress reenergized its HIV efforts in 2007.

The HIV market is very concentrated, with the top 10 brands accounting for 80% of total antiretroviral sales across the 7MM in 2007. Truvada was the bestselling drug with revenues of $1.5 billion. Gilead and BMS rapidly growing joint venture Atripla was already the fourth best selling HIV drug despite the absence of ex-US sales during the period.

While the 7MM and Canada are commercially the most significant for HIV, companies are now turning towards fast-growing emerging markets as new sources of revenue growth. The potential is there: the 7MM only account for 36% of the globally infected population, but more than 85% of revenues.

Key reasons to purchase this title

- Understand the changing market dynamics of HIV drugs, key success factors for leading brands as well as the impact of pending patent expiries

- Understand the patient acquisition process with key inflection points in the decision-making process to choose antiretroviral drug brands

- Obtain full global, country, class and product-specific forecasts of currently marketed and pipeline antiretrovirals from 2007 to 2017

Key Topics Covered:

- EXECUTIVE SUMMARY

- MARKET DEFINITION

- PATIENT ACQUISITION PROCESS

- MARKET OVERVIEW

- BRAND DYNAMICS

- KEY DEVELOPERS

- CASE STUDIES

Companies Mentioned:

- Gilead

- GlaxoSmithKline

- Tibotec

- Bristol Myers Squibb

- Abbott

- Roche

- Boehringer Ingelheim

- Merck

For more information visit http://www.researchandmarkets.com/research/b776d8/commercial_insight

Source: Datamonitor